Carl read the papersWhat it actually is
Adipotide is a peptidomimetic that binds prohibitin, a protein concentrated on the blood vessels feeding white fat. It carries a second domain that triggers apoptosis — cell death — in those vessels.
The concept is unusual: rather than suppressing appetite or raising metabolic rate, it starves fat tissue of its blood supply so the tissue itself is lost. The catch is the kidney: in monkeys the doses that worked also caused kidney tubule changes, and exactly why is not worked out.
How it’s thought to work
- Prohibitin targeting — Homes to prohibitin on the vasculature supplying white adipose tissue.
- Targeted apoptosis — The attached pro-apoptotic domain kills those endothelial cells.
- Vascular pruning — Fat tissue loses its blood supply and is resorbed. The treated monkeys also ate less, so appetite may play a part too.
- Off-target renal load — In monkeys it also hit the kidney tubules, the main side effect seen. Whether that comes from the same mechanism is not settled.
What the research says
The 2011 Barnhart primate study is the famous one — obese rhesus monkeys lost roughly 11% of body weight in four weeks. The authors called the kidney effects mild and reversible, but they showed up at the doses that worked: raised blood creatinine, glucose and protein in the urine, and damaged tubule cells. The only human trial, a phase 1 in men with prostate cancer and obesity, enrolled 4 people and was terminated in 2019 at the lead investigator's request, with no results published. Nobody has published a human therapeutic index, so there is no evidence of a safe margin.
- Barnhart 2011 (rhesus primates) — ~11% body-weight reduction in 4 weeks.
- Kidney effects in monkeys: raised blood creatinine, protein and glucose in the urine, tubule cell damage, mostly reversed within 4 weeks of stopping.
- Human phase 1 (4 patients) terminated 2019 at the investigator's request; no results published.
- In monkeys, kidney changes came with the effective dose, so there was no comfortable margin between effect and harm.
Watch: Adipotide explained
Video by Seth Spartan (The TRT King) on YouTube. Not affiliated with Peptide Carl and not an endorsement — included because a second explanation of the same mechanism is often what makes it click.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Study protocol | Published work used 28-day cycles followed by a washout — long enough for fat reduction, intended to cap cumulative renal exposure |
| Circulating figures | 0.5 mg/kg/day for 28 days is widely repeated online. It is extrapolated from monkey studies, and no human safety data has been published |
| Lower figures | Some sources cite roughly 0.01 mg/kg/day as a more conservative research dose |
| Route | Subcutaneous |
| Monitoring | Every serious protocol calls for kidney function monitoring — creatinine and eGFR — from the first week |
| Community tip | The honest community position on this compound is largely do not run it. The people who have looked closely at the phase 1 termination generally conclude the margin is too thin to manage at home. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Adipose research | 28-day cycles with washout, per the published study design |
| Why it is not a fat-loss protocol | kidney changes at the effective dose in monkeys, and no human safety data |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
Published research used subcutaneous administration in 28-day cycles with a washout period between them. The far more important point is monitoring: renal function (creatinine and eGFR) is where the monkey studies showed harm, and kidney injury produces no symptoms until it is well advanced. Anyone handling this compound without baseline and ongoing bloods has no way of knowing what is happening.
Stacks it appears in
- Not applicable — Stacking is not a meaningful discussion for a compound whose main side effect in monkeys was renal. Anything adding renal load makes the core problem worse.
Sources
- Kolonin et al., targeted ablation of fat in mice, Nat Med 2004 (PMID 15133506)
- Barnhart et al., adipotide in obese monkeys, Sci Transl Med 2011 (PMID 22072637)
- Barnhart 2011 full text (PMC3666164)
- Criscione comment on the monkey study, Sci Transl Med 2012 (PMID 22539771)
- Human phase 1 (Prohibitin-TP01), ClinicalTrials.gov NCT01262664
